BIOMARIN PHARMACEUTICAL INC
For the period ended Dec 31, 2023. Filed Feb 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 26, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Rule 10b5-1 Trading Plans
During the three months ended December 31, 2023, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of BioMarin securities set forth in the table below.
| Type of Trading Arrangement | |||||||
|---|---|---|---|---|---|---|---|
| Name | Position | Action | Adoption/TerminationDate | Rule 10b5-1(1) | Non-Rule 10b5-1(2) | Total Shares of Common Stock to be Sold(3) | Expiration Date |
| Erin Burkhart | Group Vice President and Chief Accounting Officer | Termination | November 29, 2023 | X | up to 2,782 | March 8, 2024 | |
| Erin Burkhart | Group Vice President and Chief Accounting Officer | Adoption | November 29, 2023 | X | up to 5,709 | November 29, 2024 | |
(1) Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
(2) “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act.
(3) Represents the maximum number of shares that may be sold pursuant to the 10b5-1 arrangement. The number of shares sold will be dependent on the satisfaction of certain conditions as set forth in the written plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.